成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Welcome to chemicalbook!
+1 (818) 612-2111
Inquriy
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

RFQ
skype
MY Account
Top
Postion:Product Catalog >API>Nervous system drugs>Cholinergic drugs>(-)-Huperzine A
(-)-Huperzine A
  • (-)-Huperzine A
  • (-)-Huperzine A
  • (-)-Huperzine A
  • (-)-Huperzine A
  • (-)-Huperzine A

(-)-Huperzine A NEW

Price Get Latest Price
Package 25kg
Min. Order: 1kg
Supply Ability: 2000ton
Update Time: 2024-04-12

Product Details

Product Name: (-)-Huperzine A CAS No.: 102518-79-6
EC-No.: 600-320-6 Min. Order: 1kg
Purity: 99% Supply Ability: 2000ton
Release date: 2024/04/12
Appearance: White Powder

Huperdine A is a natural alkaloid extracted from Melaleuca SPP. It is a potent, reversible and highly selective second-generation acetylcholinesterase inhibitor. It is a yellowish to white crystalline powder, soluble in chloroform, soluble in methanol, ethanol and slightly soluble in water. It has high lipid solubility, small molecule and can well permeate the blood-brain barrier. After entering the center, it distributes in the frontal lobe, temporal lobe, hippocampus and other brain regions closely related to learning and memory. At low dose, it has a strong inhibitory effect on AchE, which significantly increases the content of Ach in the synaptic gap in the distribution area, thus enhancing neuronal excitation conduction and enhancing the excitatory effect in the brain regions of learning and memory. It can improve cognitive function, enhance memory retention and promote memory reproduction. It is currently the most successful drug for the treatment of Alzheimer's disease (senile dementia) in China.


Huperzine A not only inhibits cholinesterase activity, but also affects the free radical system, reduces somatostatin, intracellular [Ca2+], glutamate content, and increases calmodulin (CaM) and calmodulin messenger RNA (CaMmRNA) expression levels and other pharmacological mechanisms to improve cognitive function and learning and memory ability.


Indication

Huperzine A is a reversible and potent cholinesterase inhibitor, which is stronger than physostigmine, neostigmine and Tacrine. For myasthenia gravis, the effective rate is 99%. Clinical trials show that this product is suitable for benign memory disorders, can improve the patients' ability of pointing memory, associative learning, image recall, meaningless figure recognition and portrait recall, and can also enhance the learning and memory of normal people. This product can also improve the memory disorders caused by dementia patients and organic brain lesions. Huperzine A can be used clinically to treat the following symptoms:

1, for the treatment and improvement of middle-aged and elderly memory function decline, improve associative recall function; For memory decline caused by excessive use of the brain, improve learning and work efficiency;

2, for neurasthenia associated with memory decline;

3, huperzine A is used for memory loss caused by cerebrovascular disorders;

4, used to improve the memory of Alzheimer's disease, improve and restore patients' cognition, memory function and improve emotional behavior abnormalities have obvious efficacy;

5, used to treat myasthenia gravis;

6. Huperzine A can improve association disorder, low cognitive function and memory loss associated with schizophrenia.

7, it can improve the memory function decline associated with a variety of brain diseases and physical diseases.


Side effect

Skin hives, abdominal pain, salivation, muscle twitching, diarrhea, and insomnia are uncommon.

When the dose is too large, it can cause dizziness, nausea, gastrointestinal discomfort, chest tightness, fatigue, bradycardia and other reactions, which can generally disappear on their own, and can be alleviated and disappeared when the reaction is obvious.

Storage Condition

Keep in a cool and dry place

Transportation

By Sea or by Air(DHL/UPS/TNT/FEDEX/EMS)

Delivery Time

7-28 days

Payment

T/T, Western Union or Bitcoin

Article illustration

Article illustration

Article illustration

Article illustration

Article illustration

Article illustration

Article illustration

Article illustration

Article illustration

Article illustration

Company Profile Introduction

Xi'an Haibo Biotechnology Co.,Ltd. is specialized in the study, production and sale of natural plant extract products,which are used in pharmaceuticaldietary supplement, food and cosmetic industries. Our company is located in Xian National High-tech Industrial Development Zone. Xian Haibo Biotech Co.,Ltd. has a number of departments including R&D, production, quality inspection, and market. The company's R&D center has a technical team specializing in research and developmentas well as advanced detection systems such as high-performance liquid chromatography, gas chromatography,and magnetic drive autoclave, experimental, pilot plant,and a number of scientific research institutions have established a good technical support relationship,with strong technical force. The company's production workshop has several plant extraction production lines, as well as advanced production equipment such as dynamic countercurrent extraction,column separatio

You may like

Recommended supplier

Product name Price   Suppliers Update time
$150.00/1kg
VIP1Y
Hebei Zhuanglai Chemical Trading Co Ltd
2024-12-10
$43.00/10mg
VIP5Y
TargetMol Chemicals Inc.
2024-11-19
$200.00/1kg
VIP1Y
Sach biotech Co.,Ltd
2024-07-08
$0.00/1KG
VIP4Y
Sinoway Industrial co., ltd.
2023-12-29
$100.00/1kg
Henan Bao Enluo International TradeCo.,LTD
2023-07-25
$0.00/1kg
VIP2Y
Wuhan Haorong Biotechnology Co.,Ltd
2023-07-17
$0.00/1KG
VIP2Y
Zhengzhou Anbu Chem Co.,Ltd
2023-06-16
$0.00/25kg
VIP2Y
Bonerge(Hunan) Lifescience Co., Ltd.
2023-06-08
$0.00/1g
VIP3Y
Wuhan Senwayer Century Chemical Co.,Ltd
2023-02-09
$100.00/1kg
Hebei Nafu Technology Co. , Ltd.
2022-11-07
  • Since: 2020-08-05
  • Address: 804, Unit 2, Building 4, i City, No. 11, South Tangyan Road, High-tech Zone, Xi 'an, Shaanxi
INQUIRY